Fedora Pharmaceuticals Inc. is focused on the discovery and development of innovative antimicrobial drug candidates aimed at combating antimicrobial resistance (AMR). One of their key products, Nacubactam, is a Phase 3-ready beta-lactamase inhibitor that operates through multiple mechanisms to inhibit various beta-lactamase enzymes and certain bacterial cell wall enzymes. This broad-spectrum activity makes Nacubactam particularly effective when used in combination with beta-lactam antibiotics, showcasing its potential in treating complicated urinary tract infections and severe respiratory infections, including those caused by resistant strains.

The company has conducted extensive non-clinical and clinical studies to evaluate the efficacy and safety of Nacubactam. In Phase 1 clinical trials, the drug was well tolerated by healthy volunteers, whether administered alone or in combination with meropenem, with no significant adverse effects on vital signs or laboratory test results. Additionally, pharmacokinetic studies have been performed in patients with renal impairment and those suffering from complicated urinary tract infections, further supporting the drug's potential for addressing serious bacterial infections in challenging patient populations.

Canada

Fedora Pharmaceuticals Inc. is dedicated to the discovery and development of novel antimicrobial drug candidates that will address the challenge of antimicrobial resistance (AMR).

Fedora is interested in exploring partnerships and/or licensing agreements with industry and academia to support its growing pipeline of product candidates. For more information on business development opportunities at Fedora, please contact Fedora at info@fedorapharma.com.

Fedora Pharmaceuticals

Company Details